What are the predominant parameters for Down syndrome risk estimation in first-trimester screening: a data mining study
Author:
Kilercik Meltem12ORCID, Yozgat Ihsan3ORCID, Serdar Muhittin A.12ORCID, Aksungar Fehime12ORCID, Göğüş Sema2ORCID, Solak Semra2ORCID, Kaya Zelal Zuhal1ORCID, Yayla Ali Murat4ORCID, Serteser Mustafa12ORCID
Affiliation:
1. Department of Medical Biochemistry , Acıbadem Mehmet Ali Aydınlar University , Istanbul , Turkey 2. Acıbadem Labmed Laboratories , Istanbul , Turkey 3. Department of Medical Biotechnology , Acıbadem Mehmet Ali Aydınlar University , Istanbul , Turkey 4. Department of Perinatology , Acıbadem Kozyatagı Hospital , Istanbul , Turkey
Abstract
Abstract
Objectives
This study aimed to evaluate the effect size of each parameter used in the first trimester Down syndrome (DS) risk analyses by using multiple regression analysis techniques.
Methods
This data mining study included data of 44,260 pregnant women screened at the Acibadem Labmed laboratories from 2010 to 2019. In this study, risk was calculated using the PRISCA software on the basis of nuchal translucency (NT), crown-rump length measurement, in vitro fertilization application, diabetes mellitus, Down syndrome story, smoking, maternal age, and the level of maternal serum biochemistry markers including pregnancy-associated plasma protein-A (PAPP-A) and free beta-human chorionic gonadotropin (hCGβ).
Results
Forty-four thousand two hundred sixty risk analysis patients result data were re-investigate, and 851 (1.93%) risk analysis results were found as positive. PAPP-A 747 (CI%, 476–1,170) times, NT value 512 (CI%, 343–764) times, DS story 21 times (CI%, 6.7–63.2) and hCGβ value 7.01 (CI%, 6.31–7.79) times affect the combined first-trimester risk analysis results.
Conclusions
We have suggested that those accurate PAPP-A levels and NT levels evaluation are the most critical point of combined risk analysis and that the risk of free hCGβ levels after PAPP-A is essential as a biochemical test.
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,Molecular Biology,Biochemistry
Reference38 articles.
1. Epstein, CJ. Down syndrome (trisomy 21). In: Scriver, CR, Beaudet, AL, Sly, WS, Valle, D, editors. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw-Hill; 2001:1223 p. 2. Nicolaides, KH, Heath, V, Liao, AW. The 11–14 week scan. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:581–94. https://doi.org/10.1053/beog.2000.0098. 3. Volpe, EP. Is down syndrome a modern disease? Perspect Biol Med 1986;29:423–36. https://doi.org/10.1353/pbm.1986.0043. 4. Sheets, KB, Crissman, BG, Feist, CD, Sell, SL, Johnson, LR, Donahue, KC, et al.. Practice guidelines for communicating a prenatal or postnatal diagnosis of down syndrome: recommendations of the national society of genetic counselors. J Genet Couns 2011;20:432–41. https://doi.org/10.1007/s10897-011-9375-8. 5. Canick, JA, Kellner, LH. First trimester screening for aneuploidy: serum biochemical markers. Semin Perinatol 1999;23:359. https://doi.org/10.1016/s0146-0005(99)80002-0.
|
|